Edition:
United Kingdom

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

43.96EUR
20 Feb 2018
Change (% chg)

€0.10 (+0.23%)
Prev Close
€43.86
Open
€43.86
Day's High
€43.98
Day's Low
€43.80
Volume
325,816
Avg. Vol
613,951
52-wk High
€45.16
52-wk Low
€10.26

Chart for

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.59
Market Cap(Mil.): €987.62
Shares Outstanding(Mil.): 61.42
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

16 Feb 2018

In diabetes war, Novo Nordisk aims to break mold with new pill

LONDON After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

06 Feb 2018

FOCUS-In diabetes war, Novo Nordisk aims to break mould with new pill

LONDON, Feb 6 After nearly a century building a company worth $125 billion based on injectable drugs, Denmark's Novo Nordisk - the world's biggest insulin maker - wants to prove this year it can transform the diabetes market with a pill.

06 Feb 2018

GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals

LONDON, Jan 31 Biotech deal-making is the hottest in more than a decade with $27.5 billion of transactions agreed this month and bankers reporting an above-average number of discussions that could lead to fresh activity through 2018.

31 Jan 2018

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros (3.41 billion pounds), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ . | Video

30 Jan 2018

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ. | Video

29 Jan 2018

UPDATE 4-Sanofi beats Novo to buy Ablynx for $4.8 bln in biotech M&A boom

* Novo Nordisk concedes defeat, seeks other bolt-on deals (Adds cumulative M&A value, debt cost, link to Novo Nordisk interview)

29 Jan 2018

LIVE MARKETS-Closing snapshot: STOXX 600 edges lower

* European shares dip * Heavy earnings week begins * AMS soars after raising outlook, doubling revenue * Sanofi buys Ablynx for 3.9 bln euros, Ablynx +20% Jan 29 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: STOXX 600 EDGES LOWER (163

29 Jan 2018

LIVE MARKETS-How much would yields need to rise to cause equities pain?

* European shares dip * Heavy earnings week begins * AMS soars after raising outlook, doubling revenue * Sanofi buys Ablynx for 3.9 bln euros, Ablynx +20% Jan 29 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net HOW MUCH WOULD YIELDS NEED TO RISE TO CAUSE

29 Jan 2018

LIVE MARKETS-"Tech won't go out of fashion"

* European shares dip * Heavy earnings week begins * AMS soars after raising outlook, doubling revenue * Sanofi buys Ablynx for 3.9 bln euros, Ablynx +20% Jan 29 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net "TECH WON'T GO OUT OF FASHION" (1507 GMT)

29 Jan 2018

Earnings vs. Estimates